gram-negative

(redirected from Gram-negative bacterial infections)
Also found in: Thesaurus, Medical, Encyclopedia.

gram-neg·a·tive

or Gram-neg·a·tive (grăm′nĕg′ə-tĭv)
adj.
Of, relating to, or being a bacterium that does not retain the violet stain used in the Gram stain method.

Gram-negative

adj
(Microbiology) designating bacteria that fail to retain the violet stain in Gram's method

Gram′-neg′ative

(græm)

adj. (often l.c.)
(of bacteria) not retaining the violet dye when stained by Gram's method.
[1905–10]

gram-negative

Relating to a group of bacteria that generally are resistant to the effects of antibiotics or the actions of the body's immune cells. Gram-negative bacteria have relatively thin cell walls and, when subjected to a specialized laboratory staining method, do not change color. Compare gram-positive.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Adj.1.Gram-negative - (of bacteria) being of or relating to a bacterium that does not retain the violet stain used in Gram's method
bacteria, bacterium - (microbiology) single-celled or noncellular spherical or spiral or rod-shaped organisms lacking chlorophyll that reproduce by fission; important as pathogens and for biochemical properties; taxonomy is difficult; often considered to be plants
disconfirming, negative - not indicating the presence of microorganisms or disease or a specific condition; "the HIV test was negative"
Translations

gram-neg·a·tive

n. gram-negativo, resultado de la aplicacion del método de Gram de decoloración de una bacteria o tejido por medio de alcohol.

Gram-negative

adj Gram negativo
References in periodicals archive ?
coli infections drug profiles covered in this research include A-3APO, AA-139, ACE-920, Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections, BNT-006, BXN-112, Debio-1454, Drug for Infectious Diseases, Drugs for Bacterial Infections, dusquetide, EcoXyn-4V, enterotoxigenic escherichia coli vaccine, enterotoxigenic escherichia coli vaccine, Escherichia coli (whole cell) vaccine, Escherichia coli vaccine, ETEC Adhesin-Based Vaccine, ETEC Vaccine, EV-035, extraintestinal pathogenic escherichia coli vaccine, GN snare, GN-4474, IMM-363, INX-201, MBX-2319, MDN-0057, Monoclonal Antibodies for Escherichia Coli Infections, NAB-7061uNAB-739, NAB-741, NOSO-95300, NP-432, NVC-727, NXC-4720, PMX-1278, PMX-1363, PMX-1405, PMX-247,
CAZ-AVI is being developed to treat a broad range of Gram-negative bacterial infections which are becoming resistant to antibiotics and pose an increasing risk to public health.
Xellia is aiming to develop new antibiotics that target Gram-negative bacterial infections, caused by, for example Pseudomonas, Klebsiella, Acinetobacter and Enterobacter species.
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
It also reviews key players involved in the therapeutic development for Gram-Negative Bacterial Infections.
meningosepticum infections are rare, accurate diagnosis is important because the species is usually resistant to multiple antibiotics, especially to those (including extended-spectrum [Beta]-lactam agents and aminoglycosides) typically prescribed for treatment of aerobic, gram-negative bacterial infections.
They resurrected the drug for use in a series of patients with Gram-negative bacterial infections resistant to quinolones, broad-spectrum cephalosporins, carbapenems, and the other commercially available agents.
AVYCAZ is an antibiotic developed to treat serious Gram-negative bacterial infections.
AstraZeneca today presented positive Phase III data demonstrating the efficacy and safety of ceftazidime-avibactam (CAZ-AVI), an investigational antibiotic being developed to treat serious Gram-negative bacterial infections including complicated intra-abdominal infections.
However, endotoxemia in liver transplant recipients has been associated with graft failure and a high mortality rate (4,5), and in gram-negative bacterial infections, the physiologic effects of endotoxin may persist after adequate antimicrobial drug treatment.
Discovered by Toyama Chemical, T-3811 is a new type of broad-spectrum quinolone antibiotic for treating Gram-positive and Gram-negative bacterial infections.

Full browser ?